Navigation Links
Evidence found for genes that affect risk of developing Alzheimer's disease

JACKSONVILLE, Fla. Through one of the largest studies yet of Alzheimers disease (AD) patients and their brothers, sisters, and children, researchers at Mayo Clinic Jacksonville have found strong evidence that genes other than the well-known susceptibility risk factor APOE4 influence who is at risk for developing the neurodegenerative disease later in life.

Studying 25 multigenerational families of individuals diagnosed with late onset Alzheimers disease (LOAD), the most common form of the disorder, as well as hundreds of other participants, the research team found that blood levels of amyloid beta (A) proteins associated with AD were significantly elevated compared to protein found in non-blood relatives, such as spouses.

These first-degree relatives were cognitively normal and age 65 or less many of them too young for symptoms of LOAD to show up.

These results indicate that genetic factors of substantial magnitude lead to significant elevations of A in the blood of asymptomatic, young individuals from extended LOAD families, says the studys lead investigator, Nilufer Ertekin-Taner, M.D., Ph.D. This fits with our hypothesis that A levels rise years before development of the disorder.

The results, which first appeared online in October of last year, will be published in the Feb. 19 issue of Neurology.

The researchers have already identified three candidate genes on chromosome 10 that is associated with LOAD, and at least one of them, the gene that produces insulin degrading enzyme (IDE), is now regarded as a prime candidate for contributing to the disease. IDE degrades both insulin and amyloid protein, and scientists hypothesize that when there is too much insulin in the brain such as due to diabetes or lower expression levels of IDE, this may lead to toxic accumulation of A.

We believe that 60 percent of the risk of developing the most common form of Alzheimers disease is genetic, and a good part of that is APOE4. But other genes are certainly contributing, and they could provide a platform for diagnosis and therapy in the future, says the studys senior author, Neill Graff-Radford, M.B.B.Ch., FRCP.

Dr. Ertekin-Taner estimates that the impact of these three genes could be as large as APOE4, which is a variant of the APOE gene that has been linked to LOAD. Between 30 percent and 70 percent of AD can be attributable to APOE, and we estimate this locus of three genes on chromosome 10 could be as important, she says. The effect of the chromosome 10 locus could be due to multiple genes, with each gene having a smaller effect size than that of APOE.

This study represents a decade of work by the Mayo researchers, who have been instrumental in discovering that one form of A known as A42 is much more toxic than the other common form of A, which is A40. They have also demonstrated that as AD progresses, A42 levels that have been rising for years begin to decline, presumably because more and more of the protein is being deposited within the brain.

Now, all known forms of early onset AD caused by genetic mutations are associated with an elevation of A42, and because there are such strong genetic determinants of these rarer forms of AD, the Mayo researchers speculated that the common late onset form may also be caused, in part, by genes that raise A levels.

In 2000, the team, led by Dr. Ertekin-Taner, published findings in Science magazine that targeted chromosome 10 as the site of some of these genes, whose function was unknown at the time. They had made the discovery by looking at 10 families of LOAD patients, and two other non-Mayo research teams published similar findings. The Neurology study is a continuation, and expansion, of that discovery.

This time, Mayo researchers collected data on 25 extended multigenerational LOAD families. In addition they studied 103 first-degree relatives of AD patients as well as a group of 116 participants in the federally-funded Mayo Clinic Study of Aging, who served as their comparison group. None of the study participants have been diagnosed with AD. They selected younger first-degree relatives and controls (age 20-65) to study so as to minimize the effect of age on A levels, and they also tested participants for their APOE variant. In a series of sub-studies in control groups, the investigators confirmed that blood A levels stayed consistent over a period of weeks, and that both A40 and A42 levels rise significantly in people over age 65 who do not have dementia.

In the young, cognitively normal first-degree relatives of LOAD patients, they found that levels of both A40 and A42 in the blood were significantly elevated, compared to their spouses (which served as the control group). Studying the other group of 103 first-degree relatives of AD patients, the researchers also found significantly higher levels of A42.

Overall, comparing first-degree relatives with non-relatives, they found that for A42, the average level for the first-degree relatives is about 1.21.3 times that of non-relatives, and for A40, it was 1.11.4 times greater. Just like measuring cholesterol in the blood, the absolute magnitude of such an increase does not have to be large in order to be worrisome, Dr. Ertekin-Taner says.

They then determined that this rise in A is not due to the APOE4 gene. On the contrary, the plasma A levels of relatives with the APOE4 gene variant were lower significantly so for A42 than the levels of those who lacked the gene. This means two things, says co-author Steven Younkin, M.D., Ph.D.: that genetic factors other than the ones already known must lead to plasma A elevations in first-degree LOAD relatives, and that there is a strong mechanistic interaction between APOE4 and A leading to increased deposition of A in the brain and hence lower plasma A levels in these subjects.

These findings indicate that there are genetic elevations in A levels in LOAD that cannot be explained by shared family environment, Dr. Younkin says.

The results also suggest that it is conceivable that plasma A, along with other information such as genetic variants, neuroimaging and cognitive test results, may be used in the future to identify individuals at risk for developing AD, before the onset of disease symptoms, Dr. Ertekin-Taner says.


Contact: Cynthia Nelson
Mayo Clinic

Related medicine news :

1. More evidence suggests diabetes drug may be dangerous
2. Evidence links anemia drugs with leukemic transformation in patients with primary myelofibrosis
3. Evidence of TB Found in 500,000-Year-Old Fossil
4. Diet and cancer prevention: New evidence for the protective effects of fruits and veggies
5. Wiley-Blackwell and U. of Penn Health Systems Center for Evidence-Based Practice launch InfoPOEMs
6. UC Davis researchers find evidence of mature heart cell potential in embryonic stem cells
7. Defining the Value of Medicine in an Evidence-Based Healthcare Marketplace
8. Scientific evidence of the significant anti-cancer effect of milk thistle
9. New Study Provides Scientific Evidence That DermaLastyl Face Cream Reduces Wrinkles
10. U of M study: Medicare lacks tools, incentives to enforce evidence-based coverage policies
11. Consumers Should Demand Evidence, Not Guesswork, On Meat-Cancer Links
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016  In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
Breaking Medicine Technology: